His sentiments were echoed by Ryan. “I think it is safe to envision a future in which PD-L1 therapy could be used in the front line, but we do need to do those confirmatory studies.”
IMvigor210 is the first trial to test the efficacy of atezolizumab as the initial treatment in patients with advanced bladder cancer. These data are encouraging, and the researchers are planning a randomized phase III trial of atezolizumab as an upfront treatment for advanced bladder cancer, according to an ASCO press release.
A randomized clinical trial of atezolizumab as an adjuvant treatment for early-stage bladder cancer is also underway. Meanwhile, there are several ongoing clinical trials exploring other immune checkpoint inhibitors, including nivolumab (Opdivo), pembrolizumab (Keytruda), and durvalumab in localized and advanced bladder cancer.
<<< View more from the 2016 ASCO Annual Meeting
- Balar AV, Galsky MD, Loriot Y, et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1. J Clin Oncol. 2016;34(suppl; abstr LBA4500).
- FDA approves new, targeted treatment for bladder cancer. US Food and Drug Administration. www.fda.gov/newsevents/newsroom/pressannouncements/ucm501762.htm. Posted May 18, 2016. Accessed June 5, 2016.
- Galsky MD, Sonpavde G. The effectiveness of chemotherapy in “real world” patients with metastatic bladder cancer. 2015 European Cancer Congress; September 25-29, 2015; Vienna, Austria. Poster 2624.